Thus, in a study examining the potential of the inactivation of the DDR barrier in leukemogenesis, Takacova et al. showed that ATM and ATR inhibitors inactivate the DDR barrier and support leukemia progression in a tamoxifen-inducible MLL fusion mouse model (Takacova et al., 2012). Here, KMT2A is linked to leukemia.